January, 2012

IMPORTANT DRUG WARNING

Dear Healthcare Professional:

Amylin Pharmaceuticals, Inc. is writing to inform you of important safety information about BYDUREON™ (exenatide extended-release for injectable suspension), a once weekly GLP–1 receptor agonist for the treatment of type 2 diabetes. The U.S. Food and Drug Administration (FDA) has approved BYDUREON as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is necessary to ensure that the benefits of BYDUREON outweigh the following potential risks including:

- Medullary Thyroid Carcinoma (MTC); and
- Acute Pancreatitis

Because of these potential risks, BYDUREON is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise.

WARNING: RISK OF THYROID C-CELL TUMORS

Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether BYDUREON causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be determined by clinical or nonclinical studies. BYDUREON is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with BYDUREON. Patients should be counseled regarding the risk and symptoms of thyroid tumors.

Potential Risk of Medullary Thyroid Carcinoma (MTC)

- Patients with thyroid nodules noted on physical examination or neck imaging should be referred to an endocrinologist for further evaluation.
- Routine monitoring of serum calcitonin (a biomarker of MTC) or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with BYDUREON. Such monitoring may increase the risk of unnecessary procedures, due to the low specificity of serum calcitonin testing for MTC and a high background incidence of thyroid disease.

Risk of Acute Pancreatitis

- Based on postmarketing data exenatide has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis.
- After initiation of BYDUREON, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting).
- If pancreatitis is suspected, BYDUREON should promptly be discontinued, confirmatory tests should be performed, and appropriate management should be initiated.
- If pancreatitis is confirmed, BYDUREON should not be restarted.
- Consider other antidiabetic therapies in patients with a history of pancreatitis.

Appropriate Patient Selection

BYDUREON:

- Is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise.
- Has not been studied in patients with a history of pancreatitis to determine whether these patients are at increased risk for pancreatitis while using BYDUREON. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
- Has not been studied in combination with insulin and concurrent use is not recommended.
- Should not be used in patients with a history of severe hypersensitivity to exenatide or any product components.

Important Information Regarding a Medullary Thyroid Carcinoma Disease Registry

Amylin is establishing a medullary thyroid carcinoma (MTC) case series registry to systematically monitor the annual incidence of MTC in the United States. This study will be designed to identify if there is any increased risk of MTC related to the introduction of BYDUREON into the marketplace and will also characterize patient medical histories related to diabetes and use of BYDUREON.

If you have any questions about the MTC registry, please call 1-877-700-7365 or visit www.BYDUREON.com/REMS.

Reporting Adverse Events

To report adverse events among patients taking BYDUREON, contact:

- Amylin (the Sponsor) at 1-877-700-7365 and/or
- FDA's MedWatch Reporting System by phone at 1-800-FDA-1088, or online at www.fda.gov/medwatch/report.htm.

This letter is not intended as a complete description of the risks associated with the use of BYDUREON. Please refer to the enclosed full Prescribing Information and Medication Guide for a complete description of risks.

Please contact our Medical Information department at 1-877-700-7365 if you have any questions about the information in this letter or the safe and effective use of BYDUREON.

Sincerely,

Lisa Porter, M.D.
Vice President, Research and Development
Amylin Pharmaceuticals, Inc.

Enclosure: BYDUREON™ (exenatide extended-release for injectable suspension) Full Prescribing Information January 2012.